High-Cell-Density Culture to Produce Plasmid DNA for Gene Therapy in E. coli - How to produce Plasmid DNA in a high-cell-density culture. - BioPharm International

ADVERTISEMENT

High-Cell-Density Culture to Produce Plasmid DNA for Gene Therapy in E. coli

Effects of Nitrogen Source on Plasmid Production

The choice of nitrogen source and the determination of its concentration are critical to the optimization of plasmid production in recombinant cell fermentation. The bacterial requirements for nitrogen can be satisfied by inorganic or organic sources. In our work, yeast extract was used and the effects of different levels in the feed were tested.


Figure 4. Effects of yeast extract concentration on plasmid production and cell growth in a 5-L fed batch fermentation process
Results (Figure 4) showed that the cell mass increased up to 28 g dry cell weight/L when the concentration of yeast extract was increased from 20 g/L to 50 g/L and the highest specific plasmid productivity (0.45 mg plasmid DNA g/L dry cell weight) was achieved. Therefore, from the viewpoint of the development of high-cell-density culture, an inorganic supply of nitrogen from complex components such as yeast extract was essential because it was more effective in supporting high plasmid yield.

CONCLUSION

With this cell culture procedure, larger amounts of the plasmid pIDKE2 were obtained in DH10B cells. The results from this study may be beneficial for the development of techniques for fed batch fermentation of E. coli cells and for the efficient production of plasmid DNA for therapeutic use in humans.

Odalys Ruiz Hernández is the principal researcher, Mariela Pérez de la Iglesia, Saily Martínez Gómez, Karelia Macias Cosme, Michel Díaz Martinez, and Yanay Proenza Jimenez are researchers in the fermentation department and Jorge Valdés Hernández is the department head. Miladys Limonta Fernández is the principal researcher in the purification department. Marta Pupo Peña is a researcher and Dinorah Torres Idahody, PhD, is the department head, both in the analytical development department, and Eduardo Martínez, PhD, is the head of the development division, all at the Center for Genetic Engineering and Biotechnology, Havana, Cuba,
+537.271.6022, ext: 5250.


blog comments powered by Disqus

ADVERTISEMENT

Lonza Introduces Risk Assessment Platform for Biopharmaceuticals
June 19, 2013
GSK Receives Offer for its Thrombosis Brands and Related Manufacturing Site
June 19, 2013
Elan Proceeds with Formal Sale Process of Company; Royalty Pharma Drops Bid
June 19, 2013
RAME-HART Technology Helps Boost Vaccine Production in Emerging Markets
June 19, 2013
Pfizer Wins Multibillion-Dollar Settlement from Teva and Sun for Infringement of Protonix Patent
June 19, 2013
Upcoming Conferences
UPCOMING CONFERENCES

Access Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA | July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA | August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA | August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA | August 20-21, 2013
Request Brochure

See All Conferences >>

ADVERTISEMENT

Author Guidelines
FindPharma
Source: BioPharm International,
Click here